|Bid||4.5500 x 3100|
|Ask||4.6500 x 1400|
|Day's Range||4.6300 - 5.4400|
|52 Week Range||1.9000 - 9.1500|
|Beta (5Y Monthly)||2.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.69|
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $4.40 per share. All of the shares in the offering are being sold by Adamas. The gross proceeds of the offering to Adamas, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $55.0 million, excluding any exercise of the underwriters’ option. Adamas has granted the underwriters a 30-day option to purchase up to an additional 1,875,000 shares of its common stock offered in the public offering. The offering is expected to close on March 1, 2021, subject to customary closing conditions.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that it has commenced an underwritten public offering of its common stock. All shares of common stock to be sold in the offering will be offered by Adamas. Adamas intends to grant the underwriters a 30-day option to purchase up to an aggregate of an additional 15% of the shares of its common stock offered in the public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 22.89% over the past year to ($0.64), which missed the estimate of ($0.51). Revenue of $21,010,000 rose by 28.52% from the same period last year, which beat the estimate of $20,960,000. Looking Ahead Adamas Pharmaceuticals Sees FY 2021 Total Operating Expenses Expenses $115M-$130M How To Listen To The Conference Call Date: Feb 23, 2021 Time: 04:30 PM View more earnings on ADMS ET Webcast URL: https://edge.media-server.com/mmc/p/9kbxdi2b Technicals 52-week high: $9.15 Company's 52-week low was at $1.90 Price action over last quarter: Up 49.86% Company Profile Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States. See more from BenzingaClick here for options trades from BenzingaEarnings Scheduled For February 23, 2021A Preview Of Adamas Pharmaceuticals's Earnings© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.